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INTRODUCTION

Tissue transplants between genetically dissimilar
individuals or, more specifically,

from one inbred strain

to another unrelated inbred strain are known as "homografts" .

Transplants between genetically uniform animals

of the same inbred strain are "isografts".
tically,

Characteris¬

homografts of mature tissue will not grow and

isografts wall.

For exploration of these and related phe¬

nomena transplantable tumor grafts, because of the ease
with w^hich this tissue can be transplanted, are often the
research tool of choice although normal tissue grafts may
be preferred in some instances.

Highly inbred strains of

mice are convenient experimental animals because of the
certainty with which genetic factors may be controlled
and the relatively low cost per animal.

The response of

a host to a graft of tumor, or normal tissue,

from a gene¬

tically dissimilar donor leading to ultimate graft rejec¬
tion and destruction is known as the "homograft reaction".
A host receiving two successive grafts from the same, or
genetica.lly similar,

foreign hosts rejects the second

graft more rapidly than the first.

This accelerated re¬

action to a second graft is termed the "second set response".
Many investigators have found that the "second set
response" under- certain conditions will not take place.
As early as 19C7 Flexner and Jobling reported that a

second
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gr?ft of a transplantable rat sarcoma grew progressively
in a. large proportion of' rats in which an initial graft
of the same tumor had previously regressed

(l).

The first

systematic studies on abrogation of the "second set response"
were done by Casey and his co-workers with the Brown-Pearce
tumor in rabbits and transplantable tumors in mice

(2-8).

In animals which were pretreated with killed homologous tu¬
mor tissues, grafts of tumor were found to grow- and metas¬
tasize more widely and rapidly.
proved specific,

Further, this effect was

in that it was only produced by killed

tissue of the tumor to be transplanted.
Kaliss demonstrated the essential unifying phenomenon
in these and similar studies pertaining to the induced sur¬
vival of tumor homograf'ts.

He found that sera produced

in mice or rabbits by inoculating killed tissues, or using
live transplants, when injected into prospective hosts
prior to grafting the tumor would insure survival of the
grafts

(9-11).

ation this

By zone electrophoresis and salt fraction¬

effect vres demonstrated to be due to an antibody

in the sera.

The active fraction was in the globulin por¬

tion, probably the gemma globulin

(12).

So the paradox

of enhanced growth of tumor grafts following prior treat¬
ment intended to heighten resistance was the result of' ex¬
posure of the graft to antiserum produced against it.
This progressive growth of a homograft of a trans¬
plantable mouse tumor in a foreign host strain of mice as

.

.

.

a result of the exposure of the graft to antiserum is
termed "immunological enhancement"

(13,14-) .

The anti¬

serum may he produced by active immunization with lyophilized tumor or liver, kidney or spleen,
of mouse to which the tumor is native

from the strain

(15-19).

Passive

immunization can be produced by injection of anti-tissue
sera

(1C-12).
Several hypotheses have been advanced as an explana¬

tion of the action of antiserum in relation to enhanced
growth of the graft.

A few are considered by Kaliss and

Bryant in their recent paper (20).

A theory not discussed

by them has been suggested by Snell

(21,29)

ham, Brent and Medawar (23).

and by Billing-

They propose that a "walling

off" of the tumor graft by the antiserum may occur w'hich
will prevent the tumor cells from antigenically stimulat¬
ing the host's lymphoid tissue and thus avoid the "cellu¬
lar response" thought to be responsible for the destruc¬
tion of the graft

(24-26).

As Snell says,

"The sugges¬

tion is that antiserum prevents or delays the antigens
of the homograft, or at least effective antigens, from
reaching the regional lymph nodes.

The nodes are thus

unable to generate the cellular immune factor which is
the principal agent of graft destruction.
this a
an

'walling off'

Snell has called

of the graft, and Billingham et al.

'afferent inhibition'

"

(22).

It was the purpose of this experiment to test the
above hypothesis and,

if possible, to shea

further light

*
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on the mechanism of' "immunological enhancement".

If tumor

cells could be found in the lymph nodes of immunologically
enhanced animals, and particularly if

they could be found

there within a short time after tumor grafting, then this
would be direct proof that the "walling off" or "afferent
inhibition" theory is fallacious.

If viable tumor cells

reach the lymph nodes, no more effective antigenic stimu¬
lus could be necessary or even possible.
this experiment is

The design of

similar, with certain technical modi¬

fications, to work of Mitchison although he found no viable
tumor cells in lymph nodes draining the area of regression
of a tumor (25,26).

MATERIALS AND METHODS

The transplantable mouse tumor used was Sarcoma I,
which is indigenous to the inbred A strain of mice and
grows in solid form when injected subcutaneously and In
ascites form when injected intraperitoneally.
of mice used were: A/Ks, A/Jax and C57BL/Ks
subline).

The strains

(a C57BL/6

A/Ks and A/Jax are genetically similar, and

grafts of Sarcoma I will grow and kill almost IOC per cent
of those inoculated within five weeks.

The C57BL/Ks strain

is normally resistant to grafts of Sarcoma
hosts Sarcoma I grafts

I.

In C57BL/Ks

characteristically grow for about

12 days then rapidly regress.

All the mice used in this

experiment were 4 to 7 months old except for the A/Jax mice
used for confirmation of tumors which were 2 to 3 months old.

.

.
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There were 4 large groups of mice.

Group I was com¬

posed of C57BL/Ks mice equally divided as to sex.

This

group received 4 intraperitoneal injections of lyophilized
Sarcoma I over a period of 13 days.

Each injection was

composed of 4 mgm dry weight of the freeze dried tumor in
0.5 ml physiological saline.
jection of lyophilized Sarcoma

Ten days after the last in¬
I each mouse received in

the flank a

subcutaneous inoculation of 600,000 cells of

Sarcoma I.

This inoculum was prepared by taking Sarcoma I

ascites fluid and counting the cells by the ordinary white
cell count procedure and diluting the ascites fluid with
physiological saline to the desired concentration oi

cells.

Group II was composed of C57BL/Ks mice equally divided
as to sex.

This group received an intraperitoneal injec¬

tion of C.5 ml of pooled anti-Sercoma I sera.

These sera

were obtained by bleeding C57BL/Ks mice after primary im¬
munization with a solid inoculum of' Sarcoma I or bleeding
after subsequent booster shots
frozen Sarcoma I.

of 1 to 10 homogenates of

They were prepared by allowing them to

remain for 2 hours at room temperature then spinning down
the clot and pipetting off the serum which was frozen at
-23°C. until used.

On the same day as the injection of the

anti-Sarcoma I serum these mice were inoculated subcuta¬
neously with 600,000 cells of Sarcoma I prepared as pre¬
viously described.
Group III v/a.s composed of C57BL/Ks mice and Group IV
of A/Ks mice.

These were equally divided as

to sex.

.

.
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They received no pretreatment, but were inoculated sub¬
cutaneously with 6CC,CCC Sarcoma

I

cells prepared as de¬

scribed above.
Each of these large groups was subdivided into 5
smaller groups

composed of 6 males ana 6 females each.

Cne of these subgroups from each large group was sacri¬
ficed 3,5,7,

end 14 days after inoculation with Sarcoma I

tumor cells.

"When the animals were sacrificed, the axil¬

lary, brachial and inguinal lymph nodes from the side of
implantation of the tumor cells were removed,

trimmed free

of fat and minced by chopping the nodes finely with scissors
in a

single drop of physiological saline on a sterile glass

slide.

This mince was injected through a. sterile trocar

intraperitoneally after a small transverse incision in the
abdominal skin had been made with sterile scissors.

All

the lymph node inoculations were made into A/Es mice, a
substrain of the A/Jax strain to which Sarcoma I is indi¬
genous.

The wound was

closed with collodion to minimize

infection or possible leakage of the injected material.
Occasionally lymph nodes were found overgrown by tumor,
and these were discarded and not transferred.

Two node

donor mice per host were used, and nodes were transferred
only from males to a male and. from females to a female.
The contralateral lymph nodes were treated in the same
way as the ipsilateral nodes

just described.

The fifth subgroups from each of the larger groups
were not sacrificed and the grovrth of the grafts was

.
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followed by periodic palpation until the mice either died
with a progreesively growing tumor or remained without an
evident sign of

growth for a consecutive period of

two

months at which time they were sacrificed and autopsied.
If no evidence of tumor was found,

they were classified

as negative.
The A/Ks mice which received the lymph nodes w^ere ob¬
served daily for the appearance of ascites or solid tumors.
When a mouse developed ascites, it was

sacrificed and 1 cc

of the ascitic fluid was injected subcutaneously into
A/Jax mice.

Slide preparations were also made of the

ascitic cells, and an autopsy was performed on each mouse.
The A/Jax mice had to develop solid tumors which grew; to
their death before the A/Ks mouse was considered to have
had tumor cells in the lymph nodes it received.

All slides

were reviewed and confirmed as showing sheets of tumor cells.
The A/Ks mice w,hich did not develop tumors w;ere observed
for 3 months and then sacrificed and autopsied to search
for any evidence of tumors.

RESULTS

The results of this

experiment are given in Table I.

Twenty four animals developed tumorous ascites.

Each

recipient group was composed of 6 males and 6 females
except In 3 groups, as noted in Table I, in which animals
died of unrelated causes.

Of the 24 animals which demon-

.
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strated that the nodes they received contained viable tumor
cells,

6 were hosts for node donors in Group I, the "ac¬

tively enhanced" group;

3 were hosts for node donors in

Group II, the "passively enhanced" group;

8 were from Group

III, the hosts whose donor's nodes were supposedly resis¬
tant;

and 7 were from Group IV, the hosts whose donor's

nodes were considered maximally susceptible to invasion
by tumor cells.

Viable tumor cells were present in the

contralateral nodes received by 5 animals.

As to sex,

12 males and 12 females died with tumorous ascites.

In

general it developed earlier in females, the first female
dying 22 days after receiving nodes, and 7 days later
8 females, as opposed to 3 males,
the tumor.

had been killed by

.

TABLE I

Key:
1: Subgroups
2: Pretreatment of' node doners
3: Lymph node doner strain
4: Days from donor tumor inoculation to sacri¬
fice end node +ransfer
Number
of recipient mice dying with tumor /
Column 5:
number inoculated with nodes
Column 6: Number of males dying / number of females dying
Column 7: Mice dying that received contralateral nodes
Column
Column
Column
Column

2

1

3

Group I:
A
Fr. dr. Sal
T5

C5JBL/KS

H

ii
it
n

Group II:
F
Anti-Sal
n
"

Group III:
K
Nothing
L
,V
M
"
N
"
0
"

Group IV:
P
Nothing
Q
R
II
S
It
T
II

serum

4

5

6

7

l/l2
1K/CF
3
3M/2F
5/12
5
0/12
0
7
14
0/11
0
not sacrificed (control

C
0
0
C
group;

1M/0F
0
7
2/12
2M/CF
0
14
0/12
not sacrificed (control

0
0
C
0
group)

3
5

1/12
0/12

**
y

0
2M/1F
IF
3M/1F
0
1M/0F
C
0
(control group)

C57BL/KS
ti
ii
ii
ii

3/12
4/12
5
1/11
7
14
0/12
not !sacrificed

A/Ks

2M/CF
0
1M/3F
1M/3F
0
0
7
0/12
1M/0F
0
14
1/12
not sacrificed (control group)

ii

it
it
ii

3

2/12

5

4/12

-

.

10

DISCUSSION

The limits of this tumor-donor-host combination should
be defined by the groups composed of A/Ks donors

(Group IV,

Table I)

since this

is the strain to which Sarcoma I is

native.

These maximally susceptible donor animals should

have produced the greatest possible number of lymph nodes
containing viable tumor cells.

As an approximate indica¬

tion of the sensitivity of the method used in this exper¬
iment, Kaliss found that 2CC to 50C Sarcoma I cells in¬
jected intraperitoneally into A/Ks mice will kill 6C per
cent of those injected in 22 to 25 days

(Kaliss, unpub¬

lished data).
The presence of viable tumor cells in lymph nodes
excised

from mice in Groups I and II is evidence that tu¬

mor grafts in "immunologically enhanced” mice are not "walled
off".

The finding of metastases as ea.rly as

3 days

(Sub¬

groups A and F) after tumor inoculation indicates that
"afferent inhibition" plays no important role in enhance¬
ment.

These results make improbable the hypothesis that

antiserum prevents or delays effective antigens of the
homogrsft from reaching the regional lymph nodes.
Viable tumor cells being present in the nodes of 8
Group III mice is at variance with the findings of Mitchison wrho "repeatedly implanted in mice susceptible to the
tumor lymph nodes draining" the area, of regression of a.
tumor in order to test for the presence of viable tumor

.

. ,

J

cells’' and found "the transferred nodes never gave rise
to tumors"

(26).

Perhaps an explanation of this discre¬

pancy lies in the different methods used to inject lymph
nodes.

Use of a trocar made possible the injection of the

entire inoculum of minced nodes, while enough of the mince
might have remained in the 19 gauge needle and the bored
out nozzle of the C.25 ml syringe used by Mitchison so
that a critical concentration of tumor cells was not in¬
jected.

Mitchison does not indicate how many nodes com¬

posed. an inoculum for a single mouse.
The fact that all of the nodes

containing viable tu¬

mor cells which were from the contralateral side of the
donor were excised on the fifth day after tumor inocula¬
tion suggests that there may be a

critical time during

which hematogenous metastases occur.

That lymphatic me¬

te stases continue to occur is demonstrated, by the animals
which received nodes on the seventh and twelfth post ino¬
culation days

(Subgroups H, M, and S).

These factors pro¬

bably vary with the host-tumor combina.tion under study.

''

•

.
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SUMMARY

Sarcoma I was inoculated into 4 groups
(1)

actively enhanced mice,

(3) unenhanced mice oi

(2) passively enhanced mice,

a, strain normally resistant to

grafts of this tumor and
this tumor is propoga.ted..
were excised at 3,5,7,

of mice:

(4) mice of the, strain in which
The lymph nodes

from these mice

and 14 day intervals after implan¬

tation and inoculated into mice to which the tumor is
digenous.

in¬

Twenty four animals developed tumors, demon¬

strating the lymph nodes they received contained viable
tumor cells.

Nine of these mice received nodes from ac¬

tively or passively enhanced doners proving that sufficient
antigenic stimulus is not lacking or delayed in immunologically enhanced animals.
"walling: off"

This makes

it seem unlikely that

or "afferent inhibition"

can be a valid ex¬

planation of the mechanism of action of antisera in this
phenomenon.

Finding viable tumor cells in lymph nodes

draining the area of regression of a tumor in eight animals
of Group III

conflicts with Mitchison's reported results.

.

7

A C57BL/Ks mouse with a subcutaneous tumor
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